Pipeline Review on Familial Hypercholesterolemia Therapeutic Industry, H1 2014

1
Familial Hypercholesterolemia (Type II
Hyperlipoproteinemia) - Pipeline Review, H1 2014
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.

• Published January 2014
• Single User PDF US 2000
• Corporate User PDF US 6000

2
Familial Hypercholesterolemia (Type II
Hyperlipoproteinemia) - Pipeline Review, H1 2014

• Familial Hypercholesterolemia (Type II
  Hyperlipoproteinemia) - Pipeline Review, H1 2014,
  provides an overview of the indications
  therapeutic pipeline. This report provides
  information on the therapeutic development for
  Familial Hypercholesterolemia (Type II
  Hyperlipoproteinemia), complete with latest
  updates, and special features on late-stage and
  discontinued projects. It also reviews key
  players involved in the therapeutic development
  for Familial Hypercholesterolemia (Type II
  Hyperlipoproteinemia). Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) - Pipeline Review, Half Year is built using
  data and information sourced from proprietary
  databases, Company/University websites, SEC
  filings, investor presentations and featured
  press releases from company/university sites and
  industry-specific third party sources.
• Inquiry Before Buying on this Report _at_
  http//www.reportsnreports.com/contacts/inquirybef
  orebuy.aspx?name274905.
• ScopeA snapshot of the global therapeutic
  scenario for Familial Hypercholesterolemia (Type
  II Hyperlipoproteinemia).A review of the
  Familial Hypercholesterolemia (Type II
  Hyperlipoproteinemia) products under development
  by companies and universities/research institutes
  based on information derived from company and
  industry-specific sources.Coverage of products
  based on various stages of development ranging
  from discovery till registration stages.
• A feature on pipeline projects on the basis of
  monotherapy and combined therapeutics.

Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
3
Familial Hypercholesterolemia (Type II
Hyperlipoproteinemia) - Pipeline Review, H1 2014

• Coverage of the Familial Hypercholesterolemia
  (Type II Hyperlipoproteinemia) pipeline on the
  basis of route of administration and molecule
  type.Key discontinued pipeline projects.Latest
  news and deals relating to the products.
• Inquire for Discount _at_ http//www.reportsnreports
  .com/contacts/discount.aspx?name274905.
• Reasons to buyIdentify and understand important
  and diverse types of therapeutics under
  development for Familial Hypercholesterolemia
  (Type II Hyperlipoproteinemia).Identify emerging
  players with potentially strong product portfolio
  and design effective counter-strategies to gain
  competitive advantage.Plan mergers and
  acquisitions effectively by identifying players
  of the most promising pipeline.Devise corrective
  measures for pipeline projects by understanding
  Familial Hypercholesterolemia (Type II
  Hyperlipoproteinemia) pipeline depth and focus of
  Indication therapeutics.
• Develop and design in-licensing and out-licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and scope.
• Modify the therapeutic portfolio by identifying
  discontinued projects and understanding the
  factors that drove them from pipeline.

Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
4
Familial Hypercholesterolemia (Type II
Hyperlipoproteinemia) - Pipeline Review, H1 2014

• List of TablesNumber of Products under
  Development for Familial Hypercholesterolemia
  (Type II Hyperlipoproteinemia), H1 2014 7Number
  of Products under Development for Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) - Comparative Analysis, H1 2014 8Number of
  Products under Development by Companies, H1 2014
  10Number of Products under Investigation by
  Universities/Institutes, H1 2014 11Comparative
  Analysis by Late Stage Development, H1 2014
  12Comparative Analysis by Clinical Stage
  Development, H1 2014 13Comparative Analysis by
  Early Stage Development, H1 2014 14Products
  under Development by Companies, H1 2014
  15Products under Investigation by
  Universities/Institutes, H1 2014 16Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) - Pipeline by Merck Co., Inc., H1 2014
  17Familial Hypercholesterolemia (Type II
  Hyperlipoproteinemia) - Pipeline by ReGenX
  Biosciences, LLC, H1 2014 18Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) - Pipeline by Cerenis Therapeutics SA, H1 2014
  19Familial Hypercholesterolemia (Type II
  Hyperlipoproteinemia) - Pipeline by Amgen
  Astellas BioPharma K.K., H1 2014 20

Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
5
Familial Hypercholesterolemia (Type II
Hyperlipoproteinemia) - Pipeline Review, H1 2014

• List of Tables (Cont..)
• Assessment by Monotherapy Products, H1 2014
  22Number of Products by Stage and Target, H1
  2014 24Number of Products by Stage and Mechanism
  of Action, H1 2014 26Number of Products by Stage
  and Route of Administration, H1 2014 28Number of
  Products by Stage and Molecule Type, H1 2014
  30Number of Products by Stage and Therapeutic
  Class, H1 2014 32Familial Hypercholesterolemia
  (Type II Hyperlipoproteinemia) Therapeutics -
  Recent Pipeline Updates, H1 2014 42Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) - Dormant Projects, H1 2014 49Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) - Discontinued Products, H1 2014 50
• List of Figures
• Number of Products under Development for Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ), H1 2014 7Number of Products under Development
  for Familial Hypercholesterolemia (Type II
  Hyperlipoproteinemia) - Comparative Analysis, H1
  2014 8Number of Products under Development by
  Companies, H1 2014 9Comparative Analysis by
  Early Stage Products, H1 2014 14

Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
6
Familial Hypercholesterolemia (Type II
Hyperlipoproteinemia) - Pipeline Review, H1 2014

• List of Figures(Cont..)
• Assessment by Monotherapy Products, H1 2014
  22Number of Products by Top 10 Target, H1 2014
  23Number of Products by Stage and Top 10 Target,
  H1 2014 24Number of Products by Top 10 Mechanism
  of Action, H1 2014 25Number of Products by Stage
  and Top 10 Mechanism of Action, H1 2014 26Number
  of Products by Top 10 Route of Administration, H1
  2014 27Number of Products by Stage and Top 10
  Route of Administration, H1 2014 28Number of
  Products by Top 10 Molecule Type, H1 2014
  29Number of Products by Stage and Top 10
  Molecule Type, H1 2014 30Number of Products by
  Top 10 Therapeutic Class, H1 2014 31Number of
  Products by Stage and Top 10 Therapeutic Class,
  H1 2014 32

Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.